{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-019049","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2022-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.219460+00:00","generated_at":"2026-06-24T16:41:21.009279+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulmatrix doses first subjects in Phase 1 trial of inhaled DHE (PUR3100) for acute migraine","bullets":["First five subjects dosed in Phase 1 trial of PUR3100, an inhaled formulation of dihydroergotamine (DHE) using iSPERSE technology.","Phase 1 is a double-dummy, double-blinded trial assessing safety, tolerability, and PK of 3 inhaled doses vs IV DHE in 24 healthy volunteers.","Data including safety, tolerability, and pharmacokinetics expected in Q4 2022 to guide dose selection for registration-enabling studies.","Dr. Margaret Wasilewski, CMO, cited oral inhalation as potentially more convenient than IV or nasal DHE with fewer side effects."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-019049","json":"https://secwatch.observer/filing/0001493152-22-019049.json","markdown":"https://secwatch.observer/filing/0001493152-22-019049.md","text":"https://secwatch.observer/filing/0001493152-22-019049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222019049/0001493152-22-019049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222019049/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T16:41:21.009279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}